Use of Hypertonic Saline in Neuroanesthesia and Neurocritical Care Practice: A Narrative Review

Abstract

Hypertonic saline (HTS) is a group of fluids containing sodium and chloride in a higher concentration as compared to physiological saline. The authors have conducted this review to evaluate the use of HTS in neuroanesthesia and neurocritical care. The articles for this narrative review on HTS were searched on databases like PubMed Central, EMBASE, and Google Scholar using the Medical Subject Headings keywords “Hypertonic Saline,” “Neuroanesthesia,” and “Neurocritical Care.” The review focuses on the mechanisms of HTS and its in routine clinical practice. The results of various comparative studies between HTS and mannitol and guidelines regarding the use of HTS have also been reviewed. HTS can be used to treat hyponatremia, reduce intracranial pressure, provide intraoperative relaxed brain, and aid in resuscitation during cardiogenic, neurogenic, and septic shock. Its side effects include renal toxicity in the case of hypernatremia, rebound intracranial hypertension, volume overload, dyselectrolytemia, phlebitis, local tissue damage, and osmotic demyelination syndrome in the case of rapid correction of serum sodium concentration.

 

MissingLinkText

Keywords

hypertonic saline - neuroanesthesia - neurocritical care

Introduction

Tonicity is the ability of an extracellular solution to make water move into or out of a cell by osmosis. A solution is considered hypertonic if its solute concentration is higher than the cell and the solutes cannot cross the membrane. Hypertonic saline (HTS) is a group of fluids containing sodium and chloride in a higher concentration as compared to physiological saline (0.9% w/v).[1] The use of HTS for the reduction of the brain bulge was published by Weed and McKibben in 1919.[2] Since then, there has been a myriad of studies using HTS in various medical and surgical conditions. The drug has proven its mettle in operation theatres, intensive care units (ICUs), and the emergency department. Numerous studies have shown that HTS is as effective as its competitor drug, mannitol. Despite proving its mettle in multiple clinical trials in varied settings time and again, HTS could not earn its place in routine clinical practice. Hence, we conducted this review to condense the vast information from the existing literature to highlight its benefits, application, side effects, and to draw a consensus regarding its clinical use.

 

MissingLinkText

Methodology

The pertinent articles for this narrative review were searched on databases like PubMed Central, EMBASE, and Google Scholar. The Medical Subject Headings keywords used were “Hypertonic Saline,” “Neuroanesthesia,” and “Neurocritical Care.” The articles were thoroughly analyzed by the authors before the final drafting of this article.

 

MissingLinkText

Pharmacology

HTS is used clinically in various concentrations ranging from 1.8 to 30% ([Table 1]).[3] Only 3 and 5% of HTS are currently approved by the Food and Drug Administration for use in patients with hyponatremia and increased intracranial pressure (ICP). To achieve volume expansion, dextrans have been added to it in a few formulations.

Table 1 Sodium concentrations and osmolarity of various concentrations of the hypertonic saline

Solution	Sodium concentration (mmol/L)	Osmolarity (mOsm/L)	Equiosmolar dose (275 mOsm)
NaCl 0.9%	154	308	892
Ringer's lactate	130	275	1000
Saline 1.7%	291	582	472
Saline 3%	513	1027	268
Saline 5%	856	1711	161
Saline 7.2%/HES 6% (200/0.6)	1232	2464	112
Saline 7.5%	1283	2566	107
Saline 7.5%/Dextran 70 6%	1283	2568	107
Saline 10%	1712	3424	80
Saline 23%	4004	8008	34
Saline 30%	5000	10,000	27.5

Abbreviation: HES, hydroxyethyl starch.

 

MissingLinkText

Mechanism of Action

There are various mechanisms through which HTS decreases the ICP, maintains the cerebral perfusion pressure (CPP), decreases neuronal toxicity, and finally prevents secondary injury ([Fig. 1]). The various effects and the underlying mechanisms are as follows.

Fig. 1 Various mechanisms of action of hypertonic saline.

• 1. Osmotic effect:

The mechanism of action of HTS is predominantly through the marked osmotic shift of fluid. Intravenous injection of HTS causes an increase in plasma osmolality and oncotic pressure, which shifts the water from the intracellular to the interstitial and intravascular space.[4] The reflection coefficient of the cell membrane for sodium is about 10 times more than that of the endothelial membrane (1 vs. 0.1), which implies that most of the fluid shift occurs from the intracellular space.[3] So, the HTS reduces the osmotic gap, cerebrospinal fluid production, and ICP, hence it improves intracranial compliance.[5]

• 2. Microcirculatory and vascular effects:

HTS normalizes the endothelial cell volume, which increases because of endothelial cell membrane ion exchange dysfunction. It increases the capillary diameter and reduces the resistance to blood flow.[6] [7] The above mechanisms improve microcirculation and counteract vasospasm and hypoperfusion by increasing cerebral blood flow (CBF).

The effect on urine output and sodium excretion is an interplay between many mechanisms of action. The increased intravascular volume and blood pressure lead to increased renal perfusion pressure, glomerular filtration rate, and decreased sodium reabsorption. Hyperosmolarity causes the release of antidiuretic hormone, but this is counteracted due to vagal stimulation and atrial natriuretic peptide release, finally leading to moderate diuresis and natriuresis.[8]

• 3. Effect on hemodynamics:

The intravenous infusion of HTS leads to osmotic shifts, increasing the intravascular volume, mean arterial pressure (MAP), stroke volume, and cardiac output. Also, the volume required for plasma expansion with HTS is less than that of normal saline.[9] The increase in MAP after a bolus of HTS lasts for 15 to 75 minutes but can be further extended by adding colloids.[10] HTS decreases the myocyte edema and causes the increased uptake of calcium, hence improving the myocardial activity.[11] [12]

• 4. Immunologic effect:

HTS-dextran prevents traumatic brain injury (TBI)-induced upregulation of leucocyte adhesion molecules, decreases the levels of tumor necrosis factor-α (TNF-α) and interleukin (IL)-10, and also improves the balance between coagulation and fibrinolysis.[13] It is also found that HTS has a role in decreasing cerebral edema by inhibiting microglia-derived TNF-α and IL-1β-induced upregulation of Na⁺-K⁺-Cl^- cotransporter.[14]

• 5. Neurochemical effect:

HTS increases the extracellular Na⁺ concentrations which return the Na⁺-glutamate cotransporter to its normal function. This mechanism helps in reducing the glutamate release and thus, prvents secondary brain injuries. The intracellular concentration of ions like Na⁺, Cl^-, and Ca⁺² are restored. All the above mechanisms lead to a reduction in neuronal excitation.[15]

 

MissingLinkText

Clinical Uses of Hypertonic Saline

HTS can be used in different clinical situations ([Fig. 2]), like reduction of raised ICP, in routine brain surgery, and shock.

Fig. 2 Uses of hypertonic saline.

• 1. Intracranial pressure reduction:

HTS can be used to reduce raised ICP in patients with TBI, subarachnoid hemorrhage (SAH), stroke, and mixed brain injury.

• (a) Traumatic brain injury:

Adult patients:

Among the available concentrations, 3 and 7.5% HTS are the most used in TBI patients. Huang et al studied the effect of a rapid infusion of 300 ml of 3% HTS over 20 minutes on ICP in severe TBI patients and found a decrease in ICP at 20 and 60 minutes.[16] Qureshi et al performed a retrospective review and concluded that prolonged infusion of HTS does not decrease the requirement for other interventions and serves no difference in in-hospital mortality.[17] The effects of 7.2% HTS on ICP, serum sodium, osmolality, cerebral, and systemic hemodynamics were studied in moderate to severe TBI patients, and found that it reduces ICP without changing the CBF.[18] Note that 7.5% HTS was found to decrease the number of intracranial hypertension episodes and rate of clinical failure compared to 20% mannitol.[19] However, when used in prehospital settings for the resuscitation of TBI patients, 7.5% HTS showed no differences in mortality or neurological outcome compared to the Ringer's lactate solution.[20] Marked reduction in cerebral water content was seen one hour after the infusion of 18% HTS among patients with refractory intracranial hypertension following TBI.[21] A retrospective study was done to compare 23.4% HTS and 20% mannitol among patients with raised ICP. It was found that the ICP reduction was similar in both groups but the mean duration of the ICP reduction by HTS was longer than mannitol (96 vs. 59 minutes).[22] Berger-Pelleiter et al performed a meta-analysis and opined that HTS cannot be recommended as a first-line hyperosmolar agent, and it does not decrease ICP and has no mortality benefits.[23] However, a meta-analysis by Han et al concluded that compared to mannitol, HTS had better ICP and CPP control at 30 to 60 minutes and lower treatment failure. There was no significant effect on the outcome.[24] Similarly, another meta-analysis by Shi et al concluded that HTS had a more sustained effect on ICP and CPP compared to mannitol.[25] [Table 2] summarizes the various studies comparing HTS and mannitol as an osmotherapy in TBI patients.[26] [27] [28] [29] [30] [31]

Table 2 Summary of the various studies comparing HTS and mannitol (M) for osmotherapy in traumatic brain injury (TBI) patients

Study	Type of study	No. of patients (episodes)	Included patients	Osmotherapy	Results
Han et al[24]	Meta-analysis	1,392	TBI with elevated ICP	HTS M	-HTS lowers ICP, increased CPP, and had lower treatment failure rate -No effect on outcome
Shi et al[25]	Meta-analysis	544	Severe TBI with elevated ICP	3% HTS 20% M	-HTS and M both reduce ICP -HTS: sustained effect on ICP
Cottenceau et al[26]	RCT	47 (165)	Severe TBIwith ICP > 15 mm Hg	7.5% HTS 20% M	-HTS and M both reduced ICP and increased CPP
Huang et al[27]	RCT	33 (238)	Severe TBIwith ICP > 20 mm Hg for more than 5 min	15% HTS 20% M	-The maximum ICP reduction, action onset, and duration of action was similar in HTS and M
Ichai et al[28]	RCT	34 (69)	Severe TBI with ICP > 25 mm Hg for more than 5 min	HSL(hypertonic saline lactate) 20% M	-HSL was superior in reducing ICP with better neurological outcome in HSL group
Jagannatha et al[29]	RCT	38 (488)	Severe TBI with ICP > 20 mm Hg for more than 10 min	3% HTS 20% M	-HTS: shorter duration of increased ICP and inotrope requirement
Mangat et al[30]	Retrospective cohort	50	Severe TBI	3% HTS20% M	-HTS is better than M in reducing ICP with shorter ICU stay and no effect on Clinical outcome
Sakellaridis et al[31]	RCT	29 (199)	Severe TBI with ICP > 20 mm Hg for more than 5 min	15% HTS 20% M	-Similar ICP reduction and duration of action

Abbreviations: CPP, cerebral perfusion pressure; HSL, hypertonic saline lactate; HTS, hypertonic saline; ICP, intracranial pressure; ICU, intensive care unit; RCT, randomized controlled trial.

Pediatric patients:

As per the pediatric head injury guidelines, 3% HTS can be used as an osmotherapy in patients with intracranial hypertension with effective doses between 2 and 5 mL/kg over 10 to 20 minutes (level II) or as a continuous infusion of 0.1 to 1 mL/kg/hour to maintain ICP less than 20 mm Hg (level III).[32] Infusion of 20% HTS was also found to decrease ICP in pediatric TBI patients.[33] [34] Kochanek et al compared the ICP measurements between 3% HTS and mannitol in pediatric patients with severe TBI and found that the HTS group had greater reductions in ICP along with an increase in CPP.[35]

Brain Trauma Foundation (BTF) guidelines suggest the use of hyperosmolar therapy to reduce ICP but not to improve neurological outcome. However, they also do not recommend any one agent over the other. Neurocritical Care Society (NCS) favored the use of HTS over mannitol for the initial management of decreasing ICP and cerebral edema in patients with TBI. They suggested that neither HTS nor mannitol has a role in improving the neurological outcome of patients with TBI. Also, they recommended against the use of HTS in the prehospital setting to improve neurological outcomes.[36]

• (b) Subarachnoid hemorrhage:

HTS can be used in SAH patients to decrease ICP and maintain CPP, CBF, and brain tissue oxygenation (PbtO2). Bentsen et al used a 2mL/kg bolus of 7.2% HTS in 6% hydroxyethyl starch (HES) during the episodes of raised ICP > 20 mm Hg in seven patients with SAH and found a decrease in ICP (58%) and an increase in CPP (26%) at 40 minutes. The effects lasted for 3 hours with no rebound hypertension.[37] However, when 7.2% saline in 6% HES was given in patients with SAH having ICP 10 to 20 mm Hg, a mean decrease in ICP of 3.3 mm Hg (7.2%) was noted. The CPP increase was also greater in the HTS group (5.6 vs. 0.2 mm Hg).[38] Tseng et al infused a 2-mL/kg bolus of 23.5% HTS in patients with SAH and found that CPP increased by 26.8% and ICP decreased by 74.7% at 1 hour. It was associated with a decrease in cerebrovascular resistance and increased CBF in ischemic regions of the brain by 20 to 50%.[39] Al-Rawi et al used an infusion of 23.5% HTS among 14 SAH patients and found a significant increase in CPP, CBF and PbtO2, with a significant decrease in ICP and the lactate-pyruvate ratio at 60 minutes.[40] NCS gave a conditional recommendation to use a symptom-based bolus dose of HTS over the conventional sodium level targeted dosing for decreasing the ICP/cerebral edema in patients with SAH (very low-quality evidence).[36] [Table 3] summarizes the various studies comparing HTS and mannitol for osmotherapy in SAH patients.[39] [40] [41]

Table 3 Summary of the various studies comparing HTS and mannitol (M) for osmotherapy in subarachnoid hemorrhage (SAH) patients

Study	Type of study	No. of patients (episodes)	Included patients	Osmotherapy	Results
Tseng et al[39]	Clinical trial	10 (17)	Poor grade SAH	23.4% HTS	HTS infusion increases regional CBF and CPP for 3 h
Al-Rawi et al[40]	Clinical trial	14	Poor grade SAH	23.5% HTS	HTS improves the CBF, tissue oxygenation, and metabolism
Al-Rawi et al[41]	Comparative study	44	Poor grade SAH	23.5% HTS	HTS increases ABP, CPP, oxygenation, increases flow velocity > 240 min, and decreases ICP > 300 min

Abbreviations: ABP, arterial blood pressure; CBF, cerebral blood flow; CPP, cerebral perfusion pressure; HTS, hypertonic saline; ICP, intracranial pressure.

• (c) Stroke:

HTS has been used in stroke patients with varying results. Schwarz et al used 75 mL of 10% HTS in patients with stroke having raised ICP not responding to the conventional therapy. They found that HTS was effective in decreasing the ICP and increasing the CPP.[42] A systematic review by Chugh et al on the effects of continuous HTS therapy in patients with acute ischemic infarcts, concluded that although HTS administration demonstrated improvement in the ICP, there was no significant improvement in the mortality and neurological/functional outcomes.[43]

NCS does not favor HTS or mannitol over each other to improve neurological outcomes in patients with acute ischemic stroke. They suggested the use of either agent to decrease ICP and cerebral edema in patients with acute ischemic stroke. In patients with ICH, they suggested symptom-based dosing or sodium-targeted infusion of HTS to manage raised ICP and cerebral edema.[36]

• (d) Mixed injuries:

Harutjunyan et al concluded that 2% HTS-HES decreases ICP for a longer duration compared to 15% mannitol in patients with raised ICP due to mixed cerebral pathologies (TBI, SAH, ICH, or brain tumor).[44] Seventy-six events of transtentorial herniation (TTH) in patients with mixed cerebral pathologies were managed with 23.4% NaCl along with conventional therapy. Clinical reversal of TTH occurred in 75% of the events.[45] So, HTS use in mixed cerebral pathologies can be beneficial.

• 2. Brain surgery:

The use of HTS during routine craniotomy can achieve a better brain relaxation score (BRS) with stable hemodynamics compared to 20% mannitol. Toung et al demonstrated that the continuous intravenous infusion of 7.5% HTS for 48 hours improves cerebral edema in affected and noninjured cerebral hemispheres compared to mannitol or furosemide.[46] Hernández-Palazón et al studied the dose–response relationship between 3 and 5 mL/kg of 3% HTS on intraoperative BRS. They found a similar effect on BRS and postoperative outcomes.[47] Rozet et al compared 7.5% HTS and 20% mannitol and found BRS to be comparable between both the groups with stable hemodynamics in the HTS group.[48] So, HTS can be used as an alternative hyperosmolar agent to achieve desirable BRS in routine supratentorial surgeries. [Table 4] summarizes the various studies comparing HTS and mannitol for decreasing the intraoperative brain bulk in patients undergoing brain surgery.[49] [50] [51] [52]

Table 4 Summary of the various studies comparing HTS and mannitol for decreasing the intraoperative brain-bulk in patients undergoing brain surgery

Study	Type of study	Osmotherapy	Results
Singla et al[49]	RCT	3% HTS 20% M	Brain relaxation score was same in both but better hemodynamic stability in HTS group
Barik et al[50]	RCT	20% M 3% HTS 8.4% NaHCO3	Better brain relaxation with 8.4% NaHCO3 than HTS and mannitol
Ali et al[51]	Randomized, double blind study	3% HTS 20% M	Better ICP reduction with HTS
Sokhal et al[52]	RCT	3% HTS 20% M	Comparable brain relaxation with HTS and M but better hemodynamic control with HTS

Abbreviations: HTS, hypertonic saline; ICP, intracranial pressure; RCT, randomized controlled trial.

• 3. Shock:

HTS can be useful in the management of different types of shock like hypovolemic, cardiogenic, neurogenic, and septic.

• I. Hypovolemic shock:

Fluid resuscitation with HTS in trauma patients restores blood volume, regains tissue perfusion, and reduces mortality.[53] Single boluses of 7.5% HTS in combination with dextran in posttrauma patients was found to increase the blood pressure successfully but sustained increase in the blood pressure beyond one hour was found in only one study.[54] [55] [56]

• II. Cardiogenic shock:

The infusion of HTS/HES increases left ventricular preload and reduces left ventricular afterload and hence leading to improvement of left ventricular systolic function.[57] A study by Gayatri et al compared the effect of a single bolus of 20% mannitol (5 mL/kg) or 3% HTS (5 mL/kg) on global myocardial function using a tissue Doppler-derived myocardial performance index in 50 adult patients undergoing elective supratentorial craniotomy and found no significant differences in myocardial performance and left ventricular filling pressure.[58] It was seen in animal studies that HTS increases cardiac performance by increasing Na⁺ concentration in the paraventricular nucleus and cerebral angiotensin receptor (AT-1) induced a positive inotropic effect.[59] Licata et al proposed HTS as a treatment for refractory heart failure along with high-dose diuretic therapy.[60] Zampieri and Caruso demonstrated the successful use of HTS as primary therapy for treatment in a 90-year patient with heart failure. The use of 100 mL of 10% HTS led to hemodynamic stabilization and improvement in the breathing pattern of the patient within 3 minutes.[61]

• III. Neurogenic shock:

HTS bolus during spinal anesthesia (iatrogenic neurogenic shock) increases blood pressure, and reduces the requirement for fluids and vasopressors.[62] Nout et al documented that the repeated injections of 5% HTS attenuated spinal cord swelling and edema as evidenced by magnetic resonance imaging in experimental spinal cord injury in animal models.[63] The HTS can be useful in neurogenic shock.

• IV. Septic shock:

The use of 7.5% HTS/Dextran 70 was associated with short-lived improvement in hemodynamic status in patients with severe sepsis compared to normal saline.[64] It can also improve the oxygen delivery and cardiac output in septic shock patients.[65] Effat et al used HTS in forty critically ill patients with septic shock, where it decreases CRP levels, improves in cardiac functions, sepsis scores, use of vasopressors, decreases ICU stay, and mechanical ventilation days.[66] So, the use of HTS can be beneficial in septic shock patients.

 

MissingLinkText

Complications

The use of HTS can be associated with the following complications:

• (1) Renal complications:

The upper safe limit of serum osmolarity is 365 mOsm/L with HTS in patients with TBI.[63] HTS resuscitation was associated with a fourfold increase in acute renal failure (ARF) and a twofold increase in mortality.[67] Hypernatremia is a risk factor for the development of ARF after SAH.[68] However, a mean serum sodium concentration of 160 ± 10 mEq/L and the highest serum sodium concentration of 182 mEq/L was not associated with the development of renal failure. Although, a positive correlation was seen between serum Na and creatinine levels.[69]

• 92) Rebound intracranial hypertension:

Although the phenomenon of rebound intracranial hypertension (RIH) is more common with the use of mannitol, continuous osmotherapy with HTS poses a risk of RIH. Prolonged hyperosmolar therapy causes the equilibration of the osmotic gradient across the blood–brain barrier (BBB). After the setting of a new balance, when the hyperosmolar the agent is stopped, water moves back into the brain following the reverse gradient.[70] [71] [72] [73] There is also the formation of “idiogenic osmoles” within the brain cells, which increase the osmotic activity and result in water retention or leaky BBB.

• (3) Osmotic demyelination syndrome:

The rapid increases in serum sodium concentrations can lead to the occurrence of osmotic demyelination syndrome, especially in chronic hyponatremic patients. However, the patients with TBI who were given HTS failed to show any evidence of central pontine myelinolysis in imaging or postmortem studies.[74]

• (4) Systemic side-effects:

Volume overload: The effect of HTS on volume expansion can act as a double-edged sword as along with increasing blood pressure, it may lead to chronic heart failure in patients with preexisting cardiopulmonary or renal dysfunction.[75]

Electrolyte imbalance: After the HTS administration, urinary loss can cause hypokalemia.[76] The high chloride load from HTS also causes hyperchloremic metabolic acidosis.[55]

• (5) Others:

Large-volume infusions of HTS are associated with coagulation dysfunction when more than 7.5% of blood volume is replaced.[77] It is due to decreased platelet aggregation, prolonged prothrombin time, and prolonged activated partial thromboplastin time. Phlebitis and local tissue damage can occur when HTS is administered through a peripheral line. HTS can increase the risk of infections due to its immunomodulatory effect.

 

MissingLinkText

Conclusion

HTS is an important hyperosmolar agent in the neuroanesthesiologists' armamentarium. It can be a potential alternative to mannitol, because of its multipronged mechanism of action and multidimensional use. The BTF recommends the use of HTS over mannitol in pediatric patients; however, in adult patients there is no agent that has been proven to be superior to the other. It can be used for controlling the ICP in patients with SAH and stroke as an alternative to mannitol. However, the mortality benefit and the effect on the outcome are quite dubious. HTS is also effective for intraoperative ICP reduction during routine brain surgeries. It also offers the benefit of maintenance of intravascular volume, especially in patients with compromised cardiac function and polytrauma. Although not well-established, HTS may play a role in hemodynamic stabilization in patients with septic and cardiogenic shock. However, its use should be well-surveilled to watch for its side effects.

 

MissingLinkText

 

MissingLinkText

Conflict of Interest

None declared.

• References

• 1 Freeman N, Welbourne J. Osmotherapy: science and evidence-based practice. BJA Educ 2018; 18 (09) 284-290
• 2 Weed LH, McKibben PS. Experimental alteration of brain bulk. Am J Physiol-Legacy Content 1919; 48: 531-558
• 3 Strandvik GF. Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure. Anaesthesia 2009; 64 (09) 990-1003
• 4 de Carvalho WB. Hypertonic solutions for pediatric patients [in Portuguese]. J Pediatr (Rio J) 2003; 79 (Suppl 2): S187-S194
• 5 Hochwald GM, Wald A, DiMattio J, Malhan C. The effects of serum osmolarity on cerebrospinal fluid volume flow. Life Sci 1974; 15 (07) 1309-1316
• 6 Shackford SR, Schmoker JD, Zhuang J. The effect of hypertonic resuscitation on pial arteriolar tone after brain injury and shock. J Trauma 1994; 37 (06) 899-908
• 7 Finberg L. Dangers to infants caused by changes in osmolal concentration. Pediatrics 1967; 40 (06) 1031-1034
• 8 Tyagi R, Donaldson K, Loftus CM, Jallo J. Hypertonic saline: a clinical review. Neurosurg Rev 2007; 30 (04) 277-289
• 9 Joseph B, Aziz H, Snell M. et al. The physiological effects of hyperosmolar resuscitation: 5% vs 3% hypertonic saline. Am J Surg 2014; 208 (05) 697-702
• 10 Gemma M, Cozzi S, Piccoli S, Magrin S, De Vitis A, Cenzato M. Hypertonic saline fluid therapy following brain stem trauma. J Neurosurg Anesthesiol 1996; 8 (02) 137-141
• 11 Thompson R, Greaves I. Hypertonic saline–hydroxyethyl starch in trauma resuscitation. J R Army Med Corps 2006; 152 (01) 6-12
• 12 Oliveira RP, Velasco I, Soriano FG, Friedman G. Clinical review: hypertonic saline resuscitation in sepsis. Crit Care 2002; 6 (05) 418-423
• 13 Rhind SG, Crnko NT, Baker AJ. et al. Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients. J Neuroinflammation 2010; 7: 5
• 14 Huang LQ, Zhu GF, Deng YY. et al. Hypertonic saline alleviates cerebral edema by inhibiting microglia-derived TNF-α and IL-1β-induced Na-K-Cl cotransporter up-regulation. J Neuroinflammation 2014; 11: 1-20
• 15 Choi DW. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci 1995; 18 (02) 58-60
• 16 Huang SJ, Chang L, Han YY, Lee YC, Tu YK. Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury. Surg Neurol 2006; 65 (06) 539-546 , discussion 546
• 17 Qureshi AI, Suarez JI, Castro A, Bhardwaj A. Use of hypertonic saline/acetate infusion in treatment of cerebral edema in patients with head trauma: experience at a single center. J Trauma 1999; 47 (04) 659-665
• 18 Munar F, Ferrer AM, de Nadal M. et al. Cerebral hemodynamic effects of 7.2% hypertonic saline in patients with head injury and raised intracranial pressure. J Neurotrauma 2000; 17 (01) 41-51
• 19 Cooper DJ, Myles PS, McDermott FT. et al; HTS Study Investigators. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA 2004; 291 (11) 1350-1357
• 20 Vialet R, Albanèse J, Thomachot L. et al. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med 2003; 31 (06) 1683-1687
• 21 Saltarini M, Massarutti D, Baldassarre M, Nardi G, De Colle C, Fabris G. Determination of cerebral water content by magnetic resonance imaging after small volume infusion of 18% hypertonic saline solution in a patient with refractory intracranial hypertension. Eur J Emerg Med 2002; 9 (03) 262-265
• 22 Ware ML, Nemani VM, Meeker M, Lee C, Morabito DJ, Manley GT. Effects of 23.4% sodium chloride solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study. Neurosurgery 2005; 57 (04) 727-736
• 23 Berger-Pelleiter E, Émond M, Lauzier F, Shields JF, Turgeon AF. Hypertonic saline in severe traumatic brain injury: a systematic review and meta-analysis of randomized controlled trials. CJEM 2016; 18 (02) 112-120
• 24 Han C, Yang F, Guo S, Zhang J. Hypertonic saline compared to mannitol for the management of elevated intracranial pressure in traumatic brain injury: a meta-analysis. Front Surg 2022; 8: 765784
• 25 Shi J, Tan L, Ye J, Hu L. Hypertonic saline and mannitol in patients with traumatic brain injury: a systematic and meta-analysis. Medicine (Baltimore) 2020; 99 (35) e21655
• 26 Cottenceau V, Masson F, Mahamid E. et al. Comparison of effects of equiosmolar doses of mannitol and hypertonic saline on cerebral blood flow and metabolism in traumatic brain injury. J Neurotrauma 2011; 28 (10) 2003-2012
• 27 Huang X, Yang L, Ye J, He S, Wang B. Equimolar doses of hypertonic agents (saline or mannitol) in the treatment of intracranial hypertension after severe traumatic brain injury. Medicine (Baltimore) 2020;99(38):e22004. [published correction appears in Medicine (Baltimore) 2021; 100: e25953]
• 28 Ichai C, Payen JF, Orban JC. et al. Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial. Intensive Care Med 2013; 39 (08) 1413-1422
• 29 Jagannatha AT, Sriganesh K, Devi BI, Rao GS. An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. J Clin Neurosci 2016; 27: 68-73
• 30 Mangat HS, Chiu YL, Gerber LM, Alimi M, Ghajar J, Härtl R. Hypertonic saline reduces cumulative and daily intracranial pressure burdens after severe traumatic brain injury. J Neurosurg 2015; 122 (01) 202-210
• 31 Sakellaridis N, Pavlou E, Karatzas S. et al. Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries. J Neurosurg 2011; 114 (02) 545-548
• 32 Adelson PD, Bratton SL, Carney NA. et al; American Association for Surgery of Trauma, Child Neurology Society, International Society for Pediatric Neurosurgery, International Trauma Anesthesia and Critical Care Society, Society of Critical Care Medicine, World Federation of Pediatric Intensive and Critical Care Societies. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury. Pediatr Crit Care Med 2003; 4 (3, Suppl): S40-S44
• 33 Simma B, Burger R, Falk M, Sacher P, Fanconi S. A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer's solution versus hypertonic saline. Crit Care Med 1998; 26 (07) 1265-1270
• 34 Fisher B, Thomas D, Peterson B. Hypertonic saline lowers raised intracranial pressure in children after head trauma. J Neurosurg Anesthesiol 1992; 4 (01) 4-10
• 35 Kochanek PM, Adelson PD, Rosario BL. et al; ADAPT Investigators. Comparison of intracranial pressure measurements before and after hypertonic saline or mannitol treatment in children with severe traumatic brain injury. JAMA Netw Open 2022; 5 (03) e220891
• 36 Cook AM, Morgan Jones G, Hawryluk GWJ. et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. Neurocrit Care 2020; 32 (03) 647-666
• 37 Bentsen G, Breivik H, Lundar T, Stubhaug A. Predictable reduction of intracranial hypertension with hypertonic saline hydroxyethyl starch: a prospective clinical trial in critically ill patients with subarachnoid haemorrhage. Acta Anaesthesiol Scand 2004; 48 (09) 1089-1095
• 38 Bentsen G, Breivik H, Lundar T, Stubhaug A. Hypertonic saline (7.2%) in 6% hydroxyethyl starch reduces intracranial pressure and improves hemodynamics in a placebo-controlled study involving stable patients with subarachnoid hemorrhage. Crit Care Med 2006; 34 (12) 2912-2917
• 39 Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ. Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke 2003; 34 (06) 1389-1396
• 40 Al-Rawi PG, Zygun D, Tseng MY, Hutchinson PJ, Matta BF, Kirkpatrick PJ. Cerebral blood flow augmentation in patients with severe subarachnoid haemorrhage. Acta Neurochir Suppl (Wien) 2005; 95 (Suppl 95): 123-127
• 41 Al-Rawi PG, Tseng MY, Richards HK. et al. Hypertonic saline in patients with poor-grade subarachnoid hemorrhage improves cerebral blood flow, brain tissue oxygen, and pH. Stroke 2010; 41 (01) 122-128
• 42 Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke 2002; 33 (01) 136-140
• 43 Chugh AJ, Maynard M, Sunshine K. et al. Role of continuous hypertonic saline in acute ischemic infarcts: a systematic literature review. J Neurocrit Care 2021; 14: 1-7
• 44 Harutjunyan L, Holz C, Rieger A, Menzel M, Grond S, Soukup J. Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial [ISRCTN62699180]. Crit Care 2005; 9 (05) R530-R540
• 45 Koenig MA, Bryan M, Lewin III JL, Mirski MA, Geocadin RG, Stevens RD. Reversal of transtentorial herniation with hypertonic saline. Neurology 2008; 70 (13) 1023-1029
• 46 Toung TJK, Tyler B, Brem H, Traystman RJ, Hurn PD, Bhardwaj A. Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. J Neurosurg Anesthesiol 2002; 14 (03) 187-193
• 47 Hernández-Palazón J, Fuentes-García D, Doménech-Asensi P. et al. A dose-response relationship study of hypertonic saline on brain relaxation during supratentorial brain tumour craniotomy. Br J Neurosurg 2018; 32 (06) 619-627
• 48 Rozet I, Tontisirin N, Muangman S. et al. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology 2007; 107 (05) 697-704
• 49 Singla A, Mathew PJ, Jangra K, Gupta SK, Soni SL. A comparison of hypertonic saline and mannitol on intraoperative brain relaxation in patients with raised intracranial pressure during supratentorial tumors resection: a randomized control trial. Neurol India 2020; 68 (01) 141-145
• 50 Barik AK, Agrawal S, Gupta P, Kumari R. Evaluation of equiosmolar 20% mannitol, 3% hypertonic saline and 8.4% sodium bicarbonate on intraoperative brain relaxation and hemodynamic parameters in patients undergoing craniotomy for supratentorial tumors: a prospective randomized study. Minerva Anestesiol 2021; 87 (09) 997-1005
• 51 Ali A, Tetik A, Sabanci PA. et al. Comparison of 3% hypertonic saline and 20% mannitol for reducing intracranial pressure in patients undergoing supratentorial brain tumor surgery: a randomized, double-blind clinical trial. J Neurosurg Anesthesiol 2018; 30 (02) 171-178
• 52 Sokhal N, Rath GP, Chaturvedi A, Singh M, Dash HH. Comparison of 20% mannitol and 3% hypertonic saline on intracranial pressure and systemic hemodynamics. J Clin Neurosci 2017; 42: 148-154
• 53 Ramesh GH, Uma JC, Farhath S. Fluid resuscitation in trauma: what are the best strategies and fluids?. Int J Emerg Med 2019; 12 (01) 38
• 54 Younes RN, Birolini D. Hypertonic/hyperoncotic solution in hypovolemic patients: experience in the emergency room. Rev Hosp Clin Fac Med Sao Paulo 2002; 57 (03) 124-128
• 55 Vassar MJ, Perry CA, Gannaway WL, Holcroft JW. 7.5% sodium chloride/dextran for resuscitation of trauma patients undergoing helicopter transport. Arch Surg 1991; 126 (09) 1065-1072
• 56 Alpar EK, Killampalli VV. Effects of hypertonic dextran in hypovolaemic shock: a prospective clinical trial. Injury 2004; 35 (05) 500-506
• 57 Goertz AW, Mehl T, Lindner KH. et al. Effect of 7.2% hypertonic saline/6% hetastarch on left ventricular contractility in anesthetized humans. Anesthesiology 1995; 82 (06) 1389-1395
• 58 Gayatri P, Misra S, Menon G, Arulvelan A, Thulaseedharan JV. Transesophageal echocardiographic evaluation of left ventricular systolic and diastolic function in response to 20% mannitol and 3% hypertonic saline infusion in neurosurgical patients undergoing craniotomy. J Neurosurg Anesthesiol 2014; 26 (03) 187-191
• 59 Frithiof R, Eriksson S, Bayard F, Svensson T, Rundgren M. Intravenous hypertonic NaCl acts via cerebral sodium-sensitive and angiotensinergic mechanisms to improve cardiac function in haemorrhaged conscious sheep. J Physiol 2007; 583 (Pt 3): 1129-1143
• 60 Licata G, Di Pasquale P, Parrinello G. et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003; 145 (03) 459-466
• 61 Zampieri FG, Caruso P. Acute treatment of uncompensated heart failure with 10% hypertonic saline and its subsequent effect on respiratory patterns. Clinics (São Paulo) 2011; 66 (04) 717-718
• 62 Järvelä K, Kööbi T, Kauppinen P, Kaukinen S. Effects of hypertonic 75 mg/ml (7.5%) saline on extracellular water volume when used for preloading before spinal anaesthesia. Acta Anaesthesiol Scand 2001; 45 (06) 776-781
• 63 Nout YS, Mihai G, Tovar CA, Schmalbrock P, Bresnahan JC, Beattie MS. Hypertonic saline attenuates cord swelling and edema in experimental spinal cord injury: a study utilizing magnetic resonance imaging. Crit Care Med 2009; 37 (07) 2160-2166
• 64 Oliveira RP, Weingartner R, Ribas EO, Moraes RS, Friedman G. Acute haemodynamic effects of a hypertonic saline/dextran solution in stable patients with severe sepsis. Intensive Care Med 2002; 28 (11) 1574-1581
• 65 Hannemann L, Reinhart K, Korell R, Spies C, Bredle DL. Hypertonic saline in stabilized hyperdynamic sepsis. Shock 1996; 5 (02) 130-134
• 66 Effat HS, Ramadan SS, Mokhtar MS, Ibrahim MM. Hypertonic saline versus isotonic saline in septic shock (effects on morbidity, mortality, and clinical outcome). Egypt J Crit Care Med 2021; 8: 43-50
• 67 The Brain Trauma Foundation, The American Association of Neurological Surgeons, The Joint Section on Neurotrauma and Critical Care. Initial management. J Neurotrauma 2000; 17 (6-7): 463-469
• 68 Huang PP, Stucky FS, Dimick AR, Treat RC, Bessey PQ, Rue LW. Hypertonic sodium resuscitation is associated with renal failure and death. Ann Surg 1995; 221 (05) 543-554
• 69 Kumar AB, Shi Y, Shotwell MS, Richards J, Ehrenfeld JM. Hypernatremia is a significant risk factor for acute kidney injury after subarachnoid hemorrhage: a retrospective analysis. Neurocrit Care 2015; 22 (02) 184-191
• 70 Videen JS, Michaelis T, Pinto P, Ross BD. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. J Clin Invest 1995; 95 (02) 788-793
• 71 Häussinger D, Laubenberger J, vom Dahl S. et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994; 107 (05) 1475-1480
• 72 Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991; 88 (01) 303-309
• 73 Olson JE, Goldfinger MD. Amino acid content of rat cerebral astrocytes adapted to hyperosmotic medium in vitro. J Neurosci Res 1990; 27 (02) 241-246
• 74 Peterson B, Khanna S, Fisher B, Marshall L. Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000; 28 (04) 1136-1143
• 75 Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med 2000; 28 (09) 3301-3313
• 76 Knapp JM. Hyperosmolar therapy in the treatment of severe head injury in children: mannitol and hypertonic saline. AACN Clin Issues 2005; 16 (02) 199-211
• 77 Tan TS, Tan KH, Ng HP, Loh MW. The effects of hypertonic saline solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment using thromboelastography. Anaesthesia 2002; 57 (07) 644-648

Publikationsverlauf

Artikel online veröffentlicht:
24. April 2023